Cargando…
Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients
BACKGROUND: Venovenous extracorporeal membrane oxygenation (VV-ECMO) is associated with a significant morbidity. There is the need to investigate long-term cognitive outcome among ARDS survivors treated with VV-ECMO. We aimed to compare the prevalence of long-term cognitive dysfunction and neuropsyc...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635548/ https://www.ncbi.nlm.nih.gov/pubmed/31312911 http://dx.doi.org/10.1186/s13613-019-0556-1 |
_version_ | 1783435903921815552 |
---|---|
author | Sylvestre, Aude Adda, Mélanie Maltese, François Lannelongue, Ariane Daviet, Florence Parzy, Gabriel Coiffard, Benjamin Roch, Antoine Loundou, Anderson Baumstarck, Karine Papazian, Laurent |
author_facet | Sylvestre, Aude Adda, Mélanie Maltese, François Lannelongue, Ariane Daviet, Florence Parzy, Gabriel Coiffard, Benjamin Roch, Antoine Loundou, Anderson Baumstarck, Karine Papazian, Laurent |
author_sort | Sylvestre, Aude |
collection | PubMed |
description | BACKGROUND: Venovenous extracorporeal membrane oxygenation (VV-ECMO) is associated with a significant morbidity. There is the need to investigate long-term cognitive outcome among ARDS survivors treated with VV-ECMO. We aimed to compare the prevalence of long-term cognitive dysfunction and neuropsychological impairment using a highly specific test in severe ARDS survivors treated or not treated with VV-ECMO. METHODS: Severe ARDS survivors treated between 2011 and 2017 in an ECMO Regional Referral Center were prospectively evaluated 2 years after their ICU discharge. Patients underwent an in-person interview and examination. The primary outcome was cognitive function, assessed by the Wechsler Adult Intelligence Scale 4th edition (WAIS-IV). Secondary outcomes included anxiety, depression, post-traumatic stress disorder (PTSD) and quality-of-life. RESULTS: We investigated 40 consecutive patients surviving from severe ARDS treated (N = 22) or not (N = 18) with VV-ECMO at a median [interquartile range] of 20 [17–22] and 22 [18–23] months after ICU discharge, respectively. Regarding the main outcome, cognitive function was below normal ranges in 12 (55%) ECMO patients and 10 (56%) non-ECMO patients (p = 0.95). Eight (36%) ECMO patients had moderate-to-severe depressive symptoms as compared with 7 (39%) non-ECMO patients (p = 0.87). Twelve (55%) ECMO patients and eight (44%) non-ECMO patients had moderate-to-severe anxiety symptoms (p = 0.53). Seven (33%) ECMO patients and eight (44%) non-ECMO patients presented a PTSD (p = 0.48). Health-related quality of life did not differ between the two groups. CONCLUSIONS: Using the WAIS-IV, VV-ECMO treatment does not appear to worsen long-term cognitive and neuropsychological outcomes in severe ARDS patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13613-019-0556-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6635548 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-66355482019-08-01 Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients Sylvestre, Aude Adda, Mélanie Maltese, François Lannelongue, Ariane Daviet, Florence Parzy, Gabriel Coiffard, Benjamin Roch, Antoine Loundou, Anderson Baumstarck, Karine Papazian, Laurent Ann Intensive Care Research BACKGROUND: Venovenous extracorporeal membrane oxygenation (VV-ECMO) is associated with a significant morbidity. There is the need to investigate long-term cognitive outcome among ARDS survivors treated with VV-ECMO. We aimed to compare the prevalence of long-term cognitive dysfunction and neuropsychological impairment using a highly specific test in severe ARDS survivors treated or not treated with VV-ECMO. METHODS: Severe ARDS survivors treated between 2011 and 2017 in an ECMO Regional Referral Center were prospectively evaluated 2 years after their ICU discharge. Patients underwent an in-person interview and examination. The primary outcome was cognitive function, assessed by the Wechsler Adult Intelligence Scale 4th edition (WAIS-IV). Secondary outcomes included anxiety, depression, post-traumatic stress disorder (PTSD) and quality-of-life. RESULTS: We investigated 40 consecutive patients surviving from severe ARDS treated (N = 22) or not (N = 18) with VV-ECMO at a median [interquartile range] of 20 [17–22] and 22 [18–23] months after ICU discharge, respectively. Regarding the main outcome, cognitive function was below normal ranges in 12 (55%) ECMO patients and 10 (56%) non-ECMO patients (p = 0.95). Eight (36%) ECMO patients had moderate-to-severe depressive symptoms as compared with 7 (39%) non-ECMO patients (p = 0.87). Twelve (55%) ECMO patients and eight (44%) non-ECMO patients had moderate-to-severe anxiety symptoms (p = 0.53). Seven (33%) ECMO patients and eight (44%) non-ECMO patients presented a PTSD (p = 0.48). Health-related quality of life did not differ between the two groups. CONCLUSIONS: Using the WAIS-IV, VV-ECMO treatment does not appear to worsen long-term cognitive and neuropsychological outcomes in severe ARDS patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13613-019-0556-1) contains supplementary material, which is available to authorized users. Springer International Publishing 2019-07-16 /pmc/articles/PMC6635548/ /pubmed/31312911 http://dx.doi.org/10.1186/s13613-019-0556-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Sylvestre, Aude Adda, Mélanie Maltese, François Lannelongue, Ariane Daviet, Florence Parzy, Gabriel Coiffard, Benjamin Roch, Antoine Loundou, Anderson Baumstarck, Karine Papazian, Laurent Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients |
title | Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients |
title_full | Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients |
title_fullStr | Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients |
title_full_unstemmed | Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients |
title_short | Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients |
title_sort | long-term neurocognitive outcome is not worsened by of the use of venovenous ecmo in severe ards patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635548/ https://www.ncbi.nlm.nih.gov/pubmed/31312911 http://dx.doi.org/10.1186/s13613-019-0556-1 |
work_keys_str_mv | AT sylvestreaude longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients AT addamelanie longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients AT maltesefrancois longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients AT lannelongueariane longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients AT davietflorence longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients AT parzygabriel longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients AT coiffardbenjamin longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients AT rochantoine longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients AT loundouanderson longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients AT baumstarckkarine longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients AT papazianlaurent longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients |